Impact of CMV Status on HIV Viral Load Decay

Completed

• Conditions: Hiv

• Registration Number: NCT03349359
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

Background: Cytomegalovirus (CMV) infection is usually observed among patients with HIV infection. No study to date has investigated the impact of CMV infection on HIV viral load decay during antiretroviral therapy.

Methods: 345 consecutive HIV patients coinfected (N=300) or not (N=45) with CMV were enrolled. Clinical, biological and virological data were collected from HIV antiretroviral therapy initiation to the day of HIV viral load undetectability if any.

Detailed Description

Not available

Study Timeline

• Study Start: 2016-11-01
• Primary Completion: 2017-01-30
• Study Completion: 2017-01-30
• Status Verified: 2017-11
• Study First Submitted: 2017-11-17
• Study First Submitted QC: 2017-11-17
• Last Update Submitted: 2017-11-17
• Study First Posted: 2017-11-21
• Last Update Posted: 2017-11-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 345

Inclusion Criteria

• HIV patients starting an antiretroviral therapy
• CMV serology available at antiretroviral therapy initiation
• HIV viral load assessed at each follow-up visit after treatment initiation

Read More

Exclusion Criteria

• HIV antiretroviral treatment initiation before June 2005

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
HIV viral load undetectability	From date of HIV therapy initiation until the date of HIV viral load undetectability (12 weeks in average after treatment initiation)	HIV viral load was assessed during the follow-up visits after the initiation of antiretroviral therapy. HIV undetectability was defined by an HIV-RNA level \<50 copies/mL.

Trial Locations

Locations (1)

Croix-Rousse Hospital, Hospices Civils de Lyon; 🇫🇷 Lyon, France